Supply Chain

Carfentanil, the most potent commercial opioid in the world, is making its way into the U.S. drug supply, causing a string of accidental overdoses and deaths.

While a two-pack of EpiPens has a list price of $608, one industry expert estimates that Amsterdam-based Mylan spends no more than $20 to produce the product, according to NBC News.

Mylan CEO Heather Bresch continues to defend the high cost of EpiPens by pointing out that middlemen in the drug's supply chain take 55 percent of the medication's list price, according to Health Affairs.

An Atlanta AIDS group filed a federal complaint against Humana and Cigna, arguing that the insurance companies' high prices for HIV medications discriminate against those with the disease, according to The Atlanta Journal-Constitution.

Since 2007, the price of EpiPens has increased by more than 400 percent, forcing some patients to pay as much as $700 for the medication. Mylan, the Canonsburg, Pa.-based company behind the life-saving medication, is facing large scrutiny from the media,…

"It's a struggle for all hospitals. It's something we talk about nearly every day."

New York Attorney General Eric Schneiderman launched an investigation Tuesday into EpiPen maker Mylan over antitrust concerns in its contracts with school systems, reported CNBC.

Tonix Pharmaceuticals' experimental drug failed to treat fibromyalgia in a recent clinical study, causing the New York–based company to focus on developing the drug as a treatment for post-traumatic stress disorder, reported Reuters.

Imprimis Pharmaceuticals developed the Imprimis Cares Access Network, a patient assistance program intended to improve access to the San Diego drugmaker's compounded medications and lower patients' out-of-pocket costs.

Logistic and transportation companies created 14,900 new jobs in August, despite a recent lull in shipping volumes and manufacturing activity in 2016, according to a report released by the U.S. Labor Department Friday.